Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets-Reference-Cited by-同舟云学术

Oral orismilast: Efficacy and safety in moderate‐to‐severe psoriasis and development of modified release tablets

Published:2023-01-18 Issue:4 Volume:37 Page:711-720
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Warren Richard B.¹,Strober Bruce²^ORCID,Silverberg Jonathan I.³^ORCID,Guttman Emma⁴^ORCID,Andres Philippe⁵,Felding Jakob⁵,Tutkunkardas Deniz⁵^ORCID,Kjøller Kim⁵,Sommer Morten O. A.⁵⁶,French Lars E.⁷⁸^ORCID

Affiliation:

1. Dermatology Centre Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester Manchester UK

2. Yale University and Central Connecticut Dermatology Connecticut New Haven USA

3. George Washington University School of Medicine and Health Sciences Washington District of Columbia USA

4. Department of Dermatology Icahn School of Medicine at Mount Sinai New York New York USA

5. UNION therapeutics A/S Hellerup Denmark

6. Novo Nordisk Foundation Center for Biosustainability Technical University of Denmark Kongens Lyngby Denmark

7. Department of Dermatology and Allergy University Hospital, Ludwig Maximilian University (LMU) Munich Munich Germany

8. Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami Florida USA

Funder

Novo Nordisk Fonden

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.18812

Reference22 articles.

1. Pathogenesis and clinical features of psoriasis

2. IL-17 and Th17 Cells

3. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

4. Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex

5. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-α and leukotriene B4 in a novel human whole blood assay

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovations in Psoriasis;Dermatologic Clinics;2024-09

2. New and emerging oral therapies for psoriasis;Drugs in Context;2024-08-01

3. The Psoriasis Treatment Pipeline;Dermatologic Clinics;2024-07

4. Current and emerging immunobiologic therapies for atopic dermatitis;Drugs & Therapy Perspectives;2024-06

5. N‐Pyridylureas as Masked Isocyanates Fort the Late‐Stage Diversification of Pyridine‐N‐Oxides;ChemistrySelect;2024-03-27